Hisamitsu Pharmaceutical Co Inc (Hisamitsu Pharmaceutical) manufactures and supplies pharmaceuticals, especially transdermal analgesics and anti-inflammatory drugs. The company operates through one reportable segment: research, development, manufacturing, and sale of pharmaceuticals. The company specializes in a wide range of healthcare products, serving both over-the-counter (OTC) and prescription markets globally. In Japan, it leads in OTC external pain relievers with popular brands such as Salonpas and Nobinobi Salonsip. Its portfolio includes Butenalock for athlete's foot and Allegra FX for sinus allergies. It also develops quasi-drugs and cosmetics. In prescription products, it offers Mohrus Tape and Mohrus PAP XR, effective for pain and inflammation, alongside hormone patches, asthma treatments, and overactive bladder patches. The company exports to over 40 countries internationally. Hisamitsu Pharmaceutical owns and operates manufacturing facilities in Tosu, and Utsunomiya, Japan; and sales offices in Kanazawa and Takamatsu, Japan. In FY2025, the capital expenditure stood at JPY13,036 million, indicating an increase of 64.8%.

The company focuses on medical research and development, particularly in patch technology. The Phase III trial results of HP-5000 (diclofenac sodium) for pain and inflammation were inconclusive, prompting further analysis of potential development. The company is currently involved in a Phase II clinical trial of HP-6050, a transdermal sedative for delirium and agitation. The company is also advancing a new sodium channel blocker for pain treatment, conducting preclinical trials following a licensing agreement with RaQualia Pharmaceutical Co Ltd. It develops and enhances over-the-counter drugs globally and in Japan. The company completed the SAGA Global Research Center in February 2024 in Tosu, Saga Prefecture, Japan to strengthen its research capabilities. In FY2025, the company spent JPY8,614 million on its R&D activities, which grew 11.9% YoY.